Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Epizyme nets $71.7mm in IPO

Executive Summary

Cancer epigenetics company Epizyme Inc. has completed its IPO, netting $71.7mm through the sale of 5.1mm shares at $15, the high end of the company’s anticipated $13-15 range. All four biotechs, including Epizyme, that filed for their IPOs in April have completed their offerings: anticoagulant developer Portola Pharmaceuticals Inc. brought in $131mm; immunology firm Receptos Inc. raised $68.3mm; and plasma therapeutics developer Kamada Inc. netted $48mm.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register